statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902...

FibroGen Shares Climb On Strong Q1 Sales

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in FibroGen Inc (FGEN), where a total volume of 13,026 contracts has been traded...

Notable Wednesday Option Activity: FGEN, PLCE, MDB

Investors eyeing a purchase of FibroGen Inc (FGEN) stock, but tentative about paying the going market price of 1.30/share, might benefit from considering selling puts among the alternative...

Commit To Buy FibroGen At $1, Earn 44.2% Annualized Using Options

FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential...

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers...

FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers

FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median...

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

FibroGen appoints Deyaa Adib as CMO

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology...

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Watchers	4,421
52-Wk Low	$0.3333
52-Wk High	$19.47

Volume	1.86M
52-Wk High	$19.47
52-Wk Low	$0.3333

FGEN FibroGen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals